Indivior PLC Ordinary Shares (INDV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) has a cash flow conversion efficiency ratio of 0.198x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.93 Million) by net assets ($-207.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Indivior PLC Ordinary Shares for the company's overall valuation and market capitalisation.
Indivior PLC Ordinary Shares - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Indivior PLC Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Indivior PLC Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indivior PLC Ordinary Shares ranked by their cash flow conversion efficiency. Explore Indivior PLC Ordinary Shares earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NLC India Limited
NSE:NLCINDIA
|
0.138x |
|
Inner Mongolia ERDOS Resources Co Ltd
SHG:600295
|
0.036x |
|
G-bits Network Technology Xiamen Co Ltd
SHG:603444
|
0.134x |
|
Telephone and Data Systems Inc
NYSE:TDS
|
0.015x |
|
Shenzhen Suntak Circuit Technology Co Ltd
SHE:002815
|
-0.011x |
|
Imeik Technology Development Co
SHE:300896
|
0.030x |
|
CCOOP Group Co Ltd
SHE:000564
|
-0.008x |
|
MDU Resources Group Inc
NYSE:MDU
|
0.091x |
Annual Cash Flow Conversion Efficiency for Indivior PLC Ordinary Shares (2016–2024)
The table below shows the annual cash flow conversion efficiency of Indivior PLC Ordinary Shares from 2016 to 2024. View current stock price of Indivior PLC Ordinary Shares for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-349.00 Million | $36.00 Million | -0.103x | +99.91% |
| 2023-12-31 | $2.76 Million | $-315.00 Million | -114.171x | -148962.80% |
| 2022-12-31 | $51.28 Million | $-3.93 Million | -0.077x | -104.47% |
| 2021-12-31 | $202.60 Million | $346.97 Million | 1.713x | +168.26% |
| 2020-12-31 | $82.00 Million | $-205.73 Million | -2.509x | -434.41% |
| 2019-12-31 | $209.00 Million | $156.80 Million | 0.750x | -82.89% |
| 2018-12-31 | $66.00 Million | $289.41 Million | 4.385x | +387.26% |
| 2017-12-31 | $-203.00 Million | $309.87 Million | -1.526x | -20.82% |
| 2016-12-31 | $-295.00 Million | $372.72 Million | -1.263x | -- |
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more